0001104659-23-119815.txt : 20231120 0001104659-23-119815.hdr.sgml : 20231120 20231120120956 ACCESSION NUMBER: 0001104659-23-119815 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20231120 DATE AS OF CHANGE: 20231120 EFFECTIVENESS DATE: 20231120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTERCEPT PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001270073 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223868459 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 001-35668 FILM NUMBER: 231421727 BUSINESS ADDRESS: STREET 1: 305 MADISON AVENUE CITY: MORRISTOWN STATE: NJ ZIP: 07960 BUSINESS PHONE: 646-747-1000 MAIL ADDRESS: STREET 1: 305 MADISON AVENUE CITY: MORRISTOWN STATE: NJ ZIP: 07960 FORMER COMPANY: FORMER CONFORMED NAME: INTERCEPT PHARMACEUTICALS INC DATE OF NAME CHANGE: 20031113 15-12G 1 tm2329172d4_1512g.htm 15-12G

As filed with the Securities and Exchange Commission on November 20, 2023

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 001-35668

INTERCEPT PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

305 Madison Avenue

Morristown, NJ 07960

(646) 747-1000

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.001 per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

   Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)		x
Rule 12g-4(a)(2)		¨
Rule 12h-3(b)(1)(i)		x
Rule 12h-3(b)(1)(ii)		¨
Rule 15d-6		¨
Rule 15d-22(b)		¨

   Approximate number of holders of record as of the certification or notice date: One (1).

   Pursuant to the requirements of the Securities Exchange Act of 1934, Intercept Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: November 20, 2023

INTERCEPT PHARMACEUTICALS, INC.

By:	/s/ Michele Cera
Name:	Michele Cera
Title:	Executive Director